GlaxoSmithKline today released Unaudited Interim Financial Statements for the three months ended 31 March 2017.
Revenue N’million
Q1 2017| N3,850
Q1 2016| N4,152
%age change|-7%
(Loss)/Profit after tax N’million
Q1 2017| N-8
Q1 2016| N116
%age change| N/A
EPS (Kobo)
Q1 2017|-1k
Q1 2016|10k
%age change|N/A%
